Pluvicto

News

Novartis' Pluvicto gets first European approval in GB

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products Regulatory Agency (MH

News

Manufacturing foul-up hits Novartis' radioligand business

Novartis has shut down production of its radioligand therapies – one of its key

News

UK grants early access to Novartis' prostate cancer radiolig...

The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary wh

News

Novartis gets first OK for radioligand Pluvicto in prostate ...

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radiolig

Novartis' Pluvicto gets first European approval in GB

Manufacturing foul-up hits Novartis' radioligand business

UK grants early access to Novartis' prostate cancer radiolig...

Novartis gets first OK for radioligand Pluvicto in prostate ...

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

Discover a new era of healthcare panel engagement: Grounded ...

Pluvicto

Editor's Picks